Recombinant protein production in prokaryotic and eukaryotic heterologous hosts for serological assays for COVID-19

位于安大略省基奇纳的Kenota Health（原ExVivo Labs）开发了一个完整的样本到结果的横向流 用于护理点医疗诊断的免疫测定测试系统。肯诺塔的技术完全融合了血液 通过直观易用的界面，实现了对样品的收集、纯化和定量分析。肯诺塔有 设计的IgG和IgM抗体测试可以在10分钟内确定COVID-19暴露。肯诺塔计划 与Seneca的生物科学和应用化学学院合作开发工艺， 制备SARS-CoV-2重组蛋白的方法。拟议项目将降低 测试和减少测试可用性延迟的风险。这些血清学检测对于确定 病原体在人群中的发病率。在未来，识别敏感和特异性SARS-CoV-2的能力 抗体可以支持卫生保健工作者的筛查，最大限度地减少病毒传播给同事的风险， 其他病人。

Kenota Health (formerly ExVivo Labs), Kitchener, ON, has developed a complete sample-to-result lateral flow immunoassay testing system for point-of-care medical diagnostics. Kenota's technology fully integrates blood collection, purification and quantitative analyte analysis with an intuitive easy-to-use interface. Kenota has designed IgG and IgM antibody tests that can determine COVID-19 exposure in 10 minutes. Kenota plans to collaborate with Seneca's School of Biological Science and Applied Chemistry to develop processes and procedures for manufacturing SARS-CoV-2 recombinant proteins. The proposed project will lower the cost of testing and reduce the risk of delays in availability of tests. These serological assays are critical in determining the incidence of a pathogen in a population. In future, the ability to identify sensitive and specific SARS-CoV-2 antibodies could support screening of health care workers, minimizing the risk of viral spread to colleagues and other patients.